EUR 1.82
(-0.27%)
Breakdown | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 199.12 Million | 160.47 Million | 118.16 Million | 180.69 Million |
Cost of Revenue | 217.43 Million | 51.21 Million | 22.19 Million | 39.71 Million |
Gross Profit | -18.3 Million | 109.25 Million | 95.96 Million | 140.98 Million |
Operating Expenses | 58.03 Million | 203.77 Million | 236.99 Million | 241.91 Million |
Selling, General and Administrative Expenses | - | 40.01 Million | 32.76 Million | 36.86 Million |
Research and Development Expenses | - | - | - | - |
Other Expenses | 58.03 Million | - | - | - |
Cost and Expenses | 275.47 Million | 254.99 Million | 259.19 Million | 281.62 Million |
Operating Income | -76.34 Million | -41.11 Million | -95.77 Million | -18.4 Million |
Interest Expense | 18.58 Million | 12.52 Million | 11.78 Million | 13.36 Million |
Income Tax Expense | -1.26 Million | -1.79 Million | -2.43 Million | 84 Thousand |
Earnings before Tax | -99.13 Million | -56.84 Million | -109.2 Million | -36.34 Million |
Net Income | -97.81 Million | -54.09 Million | -106.97 Million | -36.48 Million |
Earnings Per Share Basic | -1.09 | -0.92 | -1.84 | -0.63 |
Earnings Per Share Diluted | -1.09 | -0.92 | -1.84 | -0.63 |
Weighted Average Shares Outstanding | 89.71 Million | 58.8 Million | 58.24 Million | 58.19 Million |
Weighted Average Shares Outstanding (Diluted) | 89.71 Million | 58.8 Million | 58.24 Million | 58.19 Million |
Gross Margin | -0.09 | 0.68 | 0.81 | 0.78 |
EBIT Margin | -0.10 | -0.20 | -0.54 | -0.16 |
Profit Margin | -0.49 | -0.34 | -0.91 | -0.20 |
EBITDA | -18.96 Million | 21.39 Million | -63.29 Million | 53.26 Million |
Earnings Before Tax Margin | -0.38 | -0.26 | -0.81 | -0.10 |
Breakdown | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 | 2022 Q2 |
---|---|---|---|---|---|---|
Revenue | 38.54 Million | 38.54 Million | 54.04 Million | 199.12 Million | 54.04 Million | 45.51 Million |
Cost of Revenue | 57.79 Million | 57.79 Million | 52.16 Million | 60.74 Million | 52.16 Million | 56.55 Million |
Gross Profit | -19.24 Million | -19.24 Million | 1.88 Million | 138.38 Million | 1.88 Million | -11.04 Million |
Operating Expenses | -2.94 Million | -2.94 Million | 14.16 Million | 291.7 Million | 14.16 Million | 14.85 Million |
Selling, General and Administrative Expenses | 14.47 Million | 14.47 Million | 11.36 Million | - | 11.36 Million | 14.85 Million |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | -17.42 Million | -17.42 Million | 2.79 Million | - | 2.79 Million | 3000.00 |
Cost and Expenses | 54.84 Million | 54.84 Million | 66.32 Million | 352.44 Million | 66.32 Million | 71.41 Million |
Operating Income | -16.3 Million | -16.3 Million | -12.27 Million | -76.34 Million | -12.27 Million | -25.89 Million |
Interest Expense | - | - | - | 18.58 Million | - | - |
Income Tax Expense | 633.5 Thousand | 633.5 Thousand | 123.5 Thousand | -1.26 Million | 123.5 Thousand | 510 Thousand |
Earnings before Tax | -29.73 Million | -29.73 Million | -19.27 Million | -99.13 Million | -19.27 Million | -30.84 Million |
Net Income | -30.31 Million | -30.31 Million | -18.81 Million | -97.81 Million | -18.81 Million | -30.09 Million |
Earnings Per Share Basic | -0.17 | -0.17 | -0.16 | - | -0.16 | -0.47 |
Earnings Per Share Diluted | -0.17 | -0.17 | -0.16 | - | -0.16 | -0.47 |
Weighted Average Shares Outstanding | 175.54 Million | 175.54 Million | 115.42 Million | 89.71 Million | 115.42 Million | 63.36 Million |
Weighted Average Shares Outstanding (Diluted) | 175.54 Million | 175.54 Million | 115.42 Million | 89.71 Million | 115.42 Million | 63.36 Million |
Gross Margin | -0.50 | -0.50 | 0.03 | 0.69 | 0.03 | -0.24 |
EBIT Margin | -0.96 | -0.96 | -0.44 | - | -0.44 | -0.63 |
Profit Margin | -0.79 | -0.79 | -0.35 | -0.49 | -0.35 | -0.66 |
EBITDA | -37.08 Million | -37.08 Million | -23.98 Million | - | -23.98 Million | -28.45 Million |
Earnings Before Tax Margin | -0.42 | -0.42 | -0.23 | -0.38 | -0.23 | -0.57 |
AVA
IVSXF
6113
AJANTPHARM
7472
NSIT